<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Addict Sci Clin Pract</journal-id>
      <journal-id journal-id-type="iso-abbrev">Addict Sci Clin Pract</journal-id>
      <journal-title-group>
        <journal-title>Addiction Science &amp; Clinical Practice</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1940-0632</issn>
      <issn pub-type="epub">1940-0640</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23186390</article-id>
      <article-id pub-id-type="pmc">3509389</article-id>
      <article-id pub-id-type="publisher-id">1940-0640-7-19</article-id>
      <article-id pub-id-type="doi">10.1186/1940-0640-7-19</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Levamisole-induced leukocytoclastic vasculitis and neutropenia in a patient with cocaine use: An extensive case with necrosis of skin, soft tissue, and cartilage</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes" id="A1">
          <name>
            <surname>Arora</surname>
            <given-names>Natasha Purai</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>narora@med.wayne.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Jain</surname>
            <given-names>Tania</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>tjain@med.wayne.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Bhanot</surname>
            <given-names>Ravinder</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>rbhanot@med.wayne.edu</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Natesan</surname>
            <given-names>Suganthini Krishnan</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>skrishn@med.wayne.edu</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Internal Medicine, Wayne State University School of Medicine, Detroit Medical Center, 4201 Saint Antoine Street, Detroit, 48201, MI, USA</aff>
      <pub-date pub-type="ppub">
        <year>2012</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>9</month>
        <year>2012</year>
      </pub-date>
      <volume>7</volume>
      <issue>1</issue>
      <fpage>19</fpage>
      <lpage>19</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>12</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>9</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9;2012 Arora et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2012</copyright-year>
        <copyright-holder>Arora et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.ascpjournal.org/content/7/1/19"/>
      <abstract>
        <p>Levamisole-induced vasculitis is a relatively new entity in people who use cocaine. We describe a 44-year-old woman with a history of cocaine use who presented with a complaint of a painful rash of 2-3 month&#x2019;s duration on her extremities, cheeks, nose, and earlobes. She had not experienced fever, weight loss, alopecia, dry eyes, oral ulcers, photosensitivity, or arthralgia. Examination revealed tender purpuric eruptions with central necrosis on her nose, cheeks, earlobes, and extremities. Laboratory investigations revealed neutropenia, an elevated erythrocyte sedimentation rate (ESR), presence of lupus anticoagulant, low complement component 3 (C3), and presence of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA). A urine toxicology screen was positive for cocaine, and gas chromatography&#x2013;mass spectrometry was positive for levamisole. Skin biopsy showed leukocytoclastic vasculitis and small vessel thrombosis. Necrotic lesions of the nose led to its self-amputation. Large bullae on the lower extremities ruptured, leading to wound infection and extensive necrosis that required multiple surgical debridements. When necrosis progressed despite debridement, bilateral above-knee amputation of the legs was performed. Once new lesions stopped appearing, the patient was discharged home. Two months later, she had a recurrence related to cocaine use. To the best of our knowledge, this is only the second reported case of levamisole-induced vasculitis that required above-knee amputation.</p>
      </abstract>
      <kwd-group>
        <kwd>Levamisole</kwd>
        <kwd>Cutaneous vasculitis</kwd>
        <kwd>Retiform purpura</kwd>
        <kwd>Leukocytoclastic vasculitis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>According to July 2009 estimates, 69% of the cocaine seized by the US Drug Enforcement Administration (DEA) is adulterated with levamisole
[<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Levamisole is a veterinary antihelminthic agent that has recently been linked to vasculitis and neutropenia in people with cocaine use
[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. We describe a cocaine user with levamisole-induced necrosis of the skin, soft tissue, and cartilage resulting in nasal amputation, earlobe necrosis, and bilateral above-knee amputation (AKA). To the best of our knowledge, this is only the second case of levamisole-induced vasculitis requiring above-knee amputation to be reported in the English language literature, and it is also one of the first reported cases with laboratory confirmation of levamisole exposure.</p>
      <sec>
        <title>Case presentation</title>
        <p>A 44-year-old African American woman with history of hypertension and asthma presented to the hospital with a complaint of a painful rash on her extremities of 2-3 months&#x2019; duration. The rash first appeared on her upper extremities and then progressed to her legs, cheeks, nose, and earlobes. She denied a history of fever, weight loss, alopecia, dry mouth, oral ulcers, painful red eyes, photosensitivity, myalgia, arthralgia, joint swelling, dysphagia, miscarriages, or blood clots. The patient had a chronic history of crack cocaine use and a smoking history of five pack-years. On examination, her vital signs were stable. Skin examination revealed erythematous maculopapular purpuric lesions on her nose, cheeks, and earlobes with central blackish discoloration (Figures
<xref ref-type="fig" rid="F1">1</xref> and
<xref ref-type="fig" rid="F2">2</xref>). She had several large violaceous plaques and flaccid bullae on her upper and lower extremities and a stage-II ulcer on the medial surface of her right ankle with some serosanginuous discharge. Other physical examination results were normal.</p>
        <fig id="F1" position="float">
          <label>Figure 1</label>
          <caption>
            <p>Purpuric lesions and necrosis of both earlobes.</p>
          </caption>
          <graphic xlink:href="1940-0640-7-19-1"/>
        </fig>
        <fig id="F2" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Purpuric patches on extremities.</p>
          </caption>
          <graphic xlink:href="1940-0640-7-19-2"/>
        </fig>
        <p>Laboratory investigations revealed leukopenia with a white blood cell count (WBC) of 2,600 cells/&#x3BC;L, neutropenia with an absolute neutrophil count (ANC) of 900 cells/&#x3BC;L, an elevated erythrocyte sedimentation rate (ESR) of 47 mm/hour, presence of lupus anticoagulant, low complement component 3 (C3) (85 mg/dL), a normal coagulation profile, absence of antinuclear antibody (ANA), absence of cardiolipin antibody, presence of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) against myeloperoxidase (MPO), and absence of antiproteinase 3 (anti-PR3) antibody.</p>
        <p>Her urine toxicology screen was positive for cocaine, and gas chromatography&#x2013;mass spectrometry (GCMS) was positive for levamisole. Punch biopsy of the skin from involved areas showed leukocytoclastic vasculitis with angiocentric infiltrates of mixed inflammatory cells and small vessel thrombosis with multiple fibrin thrombi in the lumen of the vessels (Figures
<xref ref-type="fig" rid="F3">3</xref> and
<xref ref-type="fig" rid="F4">4</xref>).</p>
        <fig id="F3" position="float">
          <label>Figure 3</label>
          <caption>
            <p>Hematoxylin &amp; eosin staining of skin biopsy sample showing leuckocytoclastic vasculitis with angiocentric infiltrates of mixed inflammatory cells (white arrow) and small vessel thrombosis.</p>
          </caption>
          <graphic xlink:href="1940-0640-7-19-3"/>
        </fig>
        <fig id="F4" position="float">
          <label>Figure 4</label>
          <caption>
            <p><bold>Leukocytoclastic vasculitis.</bold> A dermal small vessel showing a neutrophilic-rich infiltrate with karyorrhexis and extravasated erythrocytes within the vessel wall and adjacent tissue. Intra-luminal fibrin thrombi are also present.</p>
          </caption>
          <graphic xlink:href="1940-0640-7-19-4"/>
        </fig>
        <p>Lesions on the lower extremities continued to expand, and those on nose, left cheek, and ears became necrotic. Large lower extremity bullae ruptured, leading to wound infection and septicemia with <italic>Staphylococcus aureus</italic>, <italic>Enterobacter cloacae,</italic> and <italic>Morganella morganii,</italic> which were treated with broad-spectrum antibiotics. At this point, skin involvement was estimated to be 35% of the total body surface area, and the patient was managed in a burn unit. Extensive and infected necrosis of the lower extremities required fascial excision of the dead skin and subcutaneous tissue. The patient underwent two further surgical debridements. Despite this, necrosis progressed, and attempts at nonoperative management were not successful. Eventually, bilateral AKA of the legs above the areas of necrotic skin was performed to control the spread of nonhealing necrotic wounds. The decision to proceed with bilateral AKA was based on the presence of a significant degree of necrosis of leg muscles and the poor functional prognosis for the lower extremities, even if the nonhealing wounds eventually closed with local wound care or skin grafts. Necrotic lesions on the nose led to its self-amputation (Figure
<xref ref-type="fig" rid="F5">5</xref>). The patient&#x2019;s pain was controlled with morphine (patient controlled analgesia). New lesions stopped appearing a few days following surgery, and she was discharged home with a prescription of gabapentin for neuropathic pain.</p>
        <fig id="F5" position="float">
          <label>Figure 5</label>
          <caption>
            <p>Necrotic lesions on the nose that eventually led to nasal septal destruction and self-amputation.</p>
          </caption>
          <graphic xlink:href="1940-0640-7-19-5"/>
        </fig>
        <p>Two months later, the patient was readmitted with new painful necrotic lesions on the amputated stumps (Figure
<xref ref-type="fig" rid="F6">6</xref>). She admitted to cocaine use three days prior to this admission. She was treated with intravenous methylprednisolone for three days followed by tapering doses of oral prednisone for seven days. Her pain and lesions improved significantly, and she was discharged home with a plan to follow up with the hospital&#x2019;s plastic surgery service for nose reconstruction.</p>
        <fig id="F6" position="float">
          <label>Figure 6</label>
          <caption>
            <p>Recurrent purpuric and necrotic lesions on the amputation stumps with repeat use of cocaine.</p>
          </caption>
          <graphic xlink:href="1940-0640-7-19-6"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Levamisole is a veterinary antihelminthic agent currently used to treat worm infestations in cattle, sheep, and pigs
[<xref ref-type="bibr" rid="B5">5</xref>]. In the past, it was used in humans to treat various autoimmune disorders and cancers because of its immunomodulatory properties
[<xref ref-type="bibr" rid="B5">5</xref>]. Levamisole-induced vasculitis (LIV) was first reported in a rheumatoid arthritis patient in 1978
[<xref ref-type="bibr" rid="B6">6</xref>]. Since 2009, levamisole has also been linked to cutaneous vasculitis in people who use cocaine.</p>
      <p>To the best of our best knowledge, 32 cases of LIV in patients with cocaine use have been reported to date
[<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B7">7</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Clinical features, laboratory results, skin biopsy findings, and the treatment of these patients are summarized in Tables
<xref ref-type="table" rid="T1">1</xref>,
<xref ref-type="table" rid="T2">2</xref> and
<xref ref-type="table" rid="T3">3</xref>. Of the 32 patients described, only eight had levamisole exposure confirmed by urinalysis or GCMS, although other authors speculated on this link based on the presence of levamisole in approximately 69% of the cocaine entering the United States. Among all the reported cases, only one (published twice by different authors, i.e., Ching et al.
[<xref ref-type="bibr" rid="B15">15</xref>] and Mouzakis et al.
[<xref ref-type="bibr" rid="B16">16</xref>]) had extensive necrosis requiring AKA. The patient was a 54-year-old man positive for p-ANCA who developed fever, agranulocytosis, and extensive skin necrosis following heavy intranasal cocaine use. Necrosis was present on more than 50% of his total body surface area, requiring thorough wound debridement, skin grafting, and left-sided AKA. Unlike our patient, AKA in this case was unilateral, and levamisole exposure was not confirmed by GCMS since the patient presented late after the likely exposure. The authors speculated that levamisole exposure was probable based on the patient&#x2019;s clinical presentation and history of cocaine use. Our patient represents the most extensive confirmed case of LIV with involvement of 35% of her total body surface area.</p>
      <table-wrap position="float" id="T1">
        <label>Table 1</label>
        <caption>
          <p>Clinical features of all reported cases of levamisole-induced cutaneous vasculitis in patients with cocaine use</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="center">
                <bold>Authors</bold>
              </th>
              <th align="center">
                <bold>Age/Sex</bold>
              </th>
              <th align="center">
                <bold>Clinical findings</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td rowspan="4" align="left" valign="top">Gross RL et al.
[<xref ref-type="bibr" rid="B3">3</xref>]<hr/></td>
              <td align="center" valign="bottom">50 years/M<hr/></td>
              <td align="left" valign="bottom">Retiform pupuric plaques with ulceration on earlobes/helix and lower extremities<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">42 years/M<hr/></td>
              <td align="left" valign="bottom">Reticulate pink/purple erythematous eruptions on legs, chest, arms, and back<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">42 years/F<hr/></td>
              <td align="left" valign="bottom">Violaceous papules, reticular-purpuric plaques on arms, breasts, legs, and ears<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">59 years/F<hr/></td>
              <td align="left" valign="bottom">Purpuric, necrotic plaques and bullae on face, ears, arms, right cheek, chest, and axilla<hr/></td>
            </tr>
            <tr>
              <td rowspan="5" align="left" valign="top">Ullrich K et al.
[<xref ref-type="bibr" rid="B4">4</xref>]<hr/></td>
              <td align="center" valign="bottom">45 years/M<hr/></td>
              <td align="left" valign="bottom">Painful necrotic purpura and skin nodules on extremities and ears<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">49 years/F<hr/></td>
              <td align="left" valign="bottom">Painful purpura on extremities, trunk, and earlobes<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">27 years/F<hr/></td>
              <td align="left" valign="bottom">Painful purpura on lower extremities, arthralgia<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">29 years/F<hr/></td>
              <td align="left" valign="bottom">Purpuric lesion with central necrosis on left foot, purpuric lesions on both ears<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">55 years/F<hr/></td>
              <td align="left" valign="bottom">Episodic rash on face, trunk, and extremities<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Bradford M et al.
[<xref ref-type="bibr" rid="B7">7</xref>]<hr/></td>
              <td align="center" valign="bottom">57 years/F<hr/></td>
              <td align="left" valign="bottom">Purpuric plaques with central necrosis on cheeks and earlobes<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">22 years/F<hr/></td>
              <td align="left" valign="bottom">Erythematous plaques with central necrosis on face, ears, legs, thighs, and buttocks<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Buchanan JA et al.
[<xref ref-type="bibr" rid="B8">8</xref>]<hr/></td>
              <td align="center" valign="bottom">Not specified/M<hr/></td>
              <td align="left" valign="bottom">Purple discoloration on left upper arm and right second toe, bilateral necrosis of ears<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Walsh NMG et al.
[<xref ref-type="bibr" rid="B9">9</xref>]<hr/></td>
              <td align="center" valign="bottom">39 years/F<hr/></td>
              <td align="left" valign="bottom">Retiform purpura, hemorrhagic bullae on legs, trunks, and buttocks<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">49 years/F<hr/></td>
              <td align="left" valign="bottom">Retiform purpura on chest, limbs, bilateral nasal mucosal ulcers<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Waller JM et al.
[<xref ref-type="bibr" rid="B10">10</xref>]<hr/></td>
              <td align="center" valign="bottom">38 years/F<hr/></td>
              <td align="left" valign="bottom">Retiform purpura with central necrosis on earlobes, cheeks, breast, extremities<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">43 years/F<hr/></td>
              <td align="left" valign="bottom">Retiform purpura with central necrosis on legs, arms, and pinna; livedo racemosa, splinter hemorrhages<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Farhat EK et al.
[<xref ref-type="bibr" rid="B11">11</xref>]<hr/></td>
              <td align="center" valign="bottom">43 years/F<hr/></td>
              <td align="left" valign="bottom">Retiform purpura with central necrosis on bilateral lower extremities<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">41 years/F<hr/></td>
              <td align="left" valign="bottom">Painful retiform purpuric patches on thighs, buttocks, trunk, upper extremities, and nasal tip<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Click J
[<xref ref-type="bibr" rid="B12">12</xref>]<hr/></td>
              <td align="center" valign="bottom">29 years/F<hr/></td>
              <td align="left" valign="bottom">Calf ulcerations, retiform purpura<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Geller L et al.
[<xref ref-type="bibr" rid="B13">13</xref>]<hr/></td>
              <td align="center" valign="bottom">50 years/F<hr/></td>
              <td align="left" valign="bottom">Stellate purpura with central necrosis on upper extremities, ears, back, and breasts<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Han C et al.
[<xref ref-type="bibr" rid="B14">14</xref>]<hr/></td>
              <td align="center" valign="bottom">52 years/F<hr/></td>
              <td align="left" valign="bottom">Painful retiform purpura with ulceration on arms, legs, nasal tip, cheeks, ears<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Ching J et al.
[<xref ref-type="bibr" rid="B15">15</xref>]/<break/>Mouzakis J et al.
[<xref ref-type="bibr" rid="B16">16</xref>]<hr/></td>
              <td align="center" valign="bottom">54 years/F<hr/></td>
              <td align="left" valign="bottom">Purpuric patches and plaques on legs, upper extremities, perinasal area, anterior trunk, face, and ears<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Jacob RS et al.
[<xref ref-type="bibr" rid="B17">17</xref>]<hr/></td>
              <td align="center" valign="bottom">41 years/F<hr/></td>
              <td align="left" valign="bottom">Tender purpuric patches and plaques on ears, legs, upper extremities, back, toes, and soles<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">48 years/F<hr/></td>
              <td align="left" valign="bottom">Tender purpuric patches and plaques on ears and left cheek<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Lung D et al.
[<xref ref-type="bibr" rid="B18">18</xref>]<hr/></td>
              <td align="center" valign="bottom">44 years/F<hr/></td>
              <td align="left" valign="bottom">Stellate, purpuric macules and plaques with central necrosis on legs, abdomen, and face<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Zwang NA et al.
[<xref ref-type="bibr" rid="B19">19</xref>]<hr/></td>
              <td align="center" valign="bottom">52 years/M<hr/></td>
              <td align="left" valign="bottom">Violaceous retiform papules/plaques on arms, legs, back, trunk, scalp, buttocks, fingers, foot, and ear<hr/></td>
            </tr>
            <tr>
              <td rowspan="4" align="left" valign="top">Chung C et al.
[<xref ref-type="bibr" rid="B20">20</xref>]<hr/></td>
              <td align="center" valign="bottom">46 years/F<hr/></td>
              <td align="left" valign="bottom">Purpura and necrosis on bilateral ears, cheeks, and upper and lower extremities<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">46 years/F<hr/></td>
              <td align="left" valign="bottom">Bilateral ear necrosis, diffuse retiform purpura with necrosis on neck, trunk, and extremities<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">37 years/M<hr/></td>
              <td align="left" valign="bottom">Tender bilateral ear purpura and necrosis, diffuse retiform purpura on trunk and extremities<hr/></td>
            </tr>
            <tr>
              <td align="center" valign="bottom">50 years/M<hr/></td>
              <td align="left" valign="bottom">Tender purpura and necrosis on both ears, purpura and bullae on trunk and extremities<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Jenkins J et al.
[<xref ref-type="bibr" rid="B21">21</xref>]<hr/></td>
              <td align="center" valign="bottom">47 years/M<hr/></td>
              <td align="left" valign="bottom">Painful retiform purpura with necrotic center on legs, ears, cheek, tongue, trunk, and genitalia<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">John S et al.
[<xref ref-type="bibr" rid="B22">22</xref>]<hr/></td>
              <td align="center" valign="bottom">52 years/F<hr/></td>
              <td align="left" valign="bottom">Painful violaceous plaques and flaccid bullae on right ankle, legs, left arm, and left breast<hr/></td>
            </tr>
            <tr>
              <td align="left">Arora et al. [current report]</td>
              <td align="center">44 years/F</td>
              <td align="left">Erythematous purpuric lesions with central necrosis on nose, cheeks, earlobes, and extremities</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap position="float" id="T2">
        <label>Table 2</label>
        <caption>
          <p>Laboratory findings of all reported cases of levamisole-induced cutaneous vasculitis in patients with cocaine use</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Authors</bold>
              </th>
              <th align="center">
                <bold>Age/Sex</bold>
              </th>
              <th align="center">
                <bold>Leucopenia and/or Neutropenia</bold>
              </th>
              <th align="center">
                <bold>Antibodies present</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td rowspan="4" align="left" valign="top">Gross RL et al.
[<xref ref-type="bibr" rid="B3">3</xref>]<hr/></td>
              <td align="left" valign="bottom">50 years/M<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -3,300/&#x3BC;L, ANC -2400/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, ANA, LAC, c-ANCA, anti-ds-DNA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">42 years/M<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -3,200/&#x3BC;L, ANC - 800/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, ANA, LAC, c-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">42 years/F<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, ANA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">59 years/F<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, ANA, anti-RNP<hr/></td>
            </tr>
            <tr>
              <td rowspan="5" align="left" valign="top">Ullrich K et al.
[<xref ref-type="bibr" rid="B4">4</xref>]<hr/></td>
              <td align="left" valign="bottom">45 years/M<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -1,900/&#x3BC;L, ANC -1,000/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, ANA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">49 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -3,500/&#x3BC;L, ANC &#x2013; 0 (zero)<hr/></td>
              <td align="left" valign="bottom">ANA, c-ANCA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">27 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -1,800/&#x3BC;L, ANC -400/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL, ANA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">29 years/F<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL, ANA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">55 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -3,700/&#x3BC;L, ANC -2,300/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Bradford M et al.
[<xref ref-type="bibr" rid="B7">7</xref>]<hr/></td>
              <td align="left" valign="bottom">57 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, ANC -500/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">22 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, ANC&#x2009;&lt;&#x2009;1,000/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Buchanan JA et al.
[<xref ref-type="bibr" rid="B8">8</xref>]<hr/></td>
              <td align="left" valign="bottom">Not specified/M<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -1,900/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">Not reported<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Walsh NMG et al.
[<xref ref-type="bibr" rid="B9">9</xref>]<hr/></td>
              <td align="left" valign="bottom">39 years/F<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, ANA, LAC, anti-HNE<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">49 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -2,000/&#x3BC;L, ANC -400/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, ANA, anti-HNE<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Waller JM et al.
[<xref ref-type="bibr" rid="B10">10</xref>]<hr/></td>
              <td align="left" valign="bottom">38 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, ANC -550/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, LAC<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">43 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, ANC -560/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, IgM ACL, LAC, anti-ds-DNA,<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Farhat EK et al.
[<xref ref-type="bibr" rid="B11">11</xref>]<hr/></td>
              <td align="left" valign="bottom">43 years/F<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">41 years/F<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Click J
[<xref ref-type="bibr" rid="B12">12</xref>]<hr/></td>
              <td align="left" valign="bottom">29 years/F<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, ANA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Geller L et al.
[<xref ref-type="bibr" rid="B13">13</xref>]<hr/></td>
              <td align="left" valign="bottom">50 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -2,700/&#x3BC;L, ANC -1,400/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Han C et al.
[<xref ref-type="bibr" rid="B14">14</xref>]<hr/></td>
              <td align="left" valign="bottom">52 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -2,400/&#x3BC;L, ANC -1,400/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Ching J et al.
[<xref ref-type="bibr" rid="B15">15</xref>]/<break/>Mouzakis J et al.
[<xref ref-type="bibr" rid="B16">16</xref>]<hr/></td>
              <td align="left" valign="bottom">54 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -3,900/&#x3BC;L, ANC -300/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Jacob RS et al.
[<xref ref-type="bibr" rid="B17">17</xref>]<hr/></td>
              <td align="left" valign="bottom">41 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -1,100/&#x3BC;L, ANC -670/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL, ANA, anti-ds-DNA,anti-HNE<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">48 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -800/&#x3BC;L, ANC -300/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL, ANA, anti-ds-DNA,anti-HNE<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Lung D et al.
[<xref ref-type="bibr" rid="B18">18</xref>]<hr/></td>
              <td align="left" valign="bottom">44 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, ANC -270/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">Not reported<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Zwang NA et al.
[<xref ref-type="bibr" rid="B19">19</xref>]<hr/></td>
              <td align="left" valign="bottom">52 years/M<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL, ANA, LAC, anti-HNE,<break/>anti-ds-DNA,<hr/></td>
            </tr>
            <tr>
              <td rowspan="4" align="left" valign="top">Chung C et al.
[<xref ref-type="bibr" rid="B20">20</xref>]<hr/></td>
              <td align="left" valign="bottom">46 years/F<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">46 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC and ANC not specified<hr/></td>
              <td align="left" valign="bottom">p-ANCA, c-ANCA, IgM ACL<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">37 years/M<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, ANA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">50 years/M<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA, ANA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Jenkins J et al.
[<xref ref-type="bibr" rid="B21">21</xref>]<hr/></td>
              <td align="left" valign="bottom">47 years/M<hr/></td>
              <td align="left" valign="bottom">No<hr/></td>
              <td align="left" valign="bottom">p-ANCA<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">John S et al.
[<xref ref-type="bibr" rid="B22">22</xref>]<hr/></td>
              <td align="left" valign="bottom">52 years/F<hr/></td>
              <td align="left" valign="bottom">Yes, WBC -2,900/&#x3BC;L, ANC -638/&#x3BC;L<hr/></td>
              <td align="left" valign="bottom">p-ANCA +,<break/>anti ds-DNA+<hr/></td>
            </tr>
            <tr>
              <td align="left">Arora et al. [current report]</td>
              <td align="left">44 years/F</td>
              <td align="left">Yes, WBC -2,600/&#x3BC;L, ANC -900/&#x3BC;L</td>
              <td align="left">p-ANCA+, LAC+</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>Abbreviations: <italic>M</italic>&#x2009;=&#x2009;male, <italic>F</italic>&#x2009;=&#x2009;female, <italic>WBC</italic>&#x2009;=&#x2009;white blood cell count, <italic>ANC</italic>&#x2009;=&#x2009;absolute neutrophil count, <italic>p-ANCA</italic>&#x2009;=&#x2009;perinuclear anti-neutrophil cytoplasmic antibody, <italic>c-ANCA</italic>&#x2009;=&#x2009;cytoplasmic anti-neutrophil cytoplasmic antibody, <italic>IgM ACL</italic>&#x2009;=&#x2009;immunoglobulin-M anticardiolipin antibody, <italic>ANA</italic>&#x2009;=&#x2009;antinuclear antibody, <italic>LAC</italic>&#x2009;=&#x2009;lupus anti-coagulant, anti-<italic>HNE</italic>&#x2009;=&#x2009;anti-human neutrophil elastase antibody, anti-<italic>ds-DNA</italic>&#x2009;=&#x2009;anti-double-stranded deoxyribonucleic acid antibody, anti-<italic>RNP</italic>&#x2009;=&#x2009;anti-ribonucleoprotein antibody.</p>
        </table-wrap-foot>
      </table-wrap>
      <table-wrap position="float" id="T3">
        <label>Table 3</label>
        <caption>
          <p>Skin biopsy findings, treatment, and response to treatment information of all reported cases of levamisole-induced cutaneous vasculitis</p>
        </caption>
        <table frame="hsides" rules="groups" border="1">
          <colgroup>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
            <col align="left"/>
          </colgroup>
          <thead valign="top">
            <tr>
              <th align="left">
                <bold>Authors</bold>
              </th>
              <th align="center">
                <bold>Age/Sex</bold>
              </th>
              <th align="center">
                <bold>Pathology</bold>
              </th>
              <th align="center">
                <bold>Treatment</bold>
              </th>
              <th align="center">
                <bold>Response</bold>
              </th>
            </tr>
          </thead>
          <tbody valign="top">
            <tr>
              <td rowspan="4" align="left" valign="top">Gross RL et al.
[<xref ref-type="bibr" rid="B3">3</xref>]<hr/></td>
              <td align="left" valign="bottom">50 years/M<hr/></td>
              <td align="left" valign="bottom">Vasculitis, thrombosis, necrosis<hr/></td>
              <td align="left" valign="bottom">Oral prednisone, surgical debridement<hr/></td>
              <td align="left" valign="bottom">Lesions remained stable, developed auditory hallucinations &amp; superinfection<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">42 years/M<hr/></td>
              <td align="left" valign="bottom">Small-vessel vasculitis<hr/></td>
              <td align="left" valign="bottom">Supportive care<hr/></td>
              <td align="left" valign="bottom">Lesions improved without any intervention<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">42 years/F<hr/></td>
              <td align="left" valign="bottom">Lekocytoclastic vasculitis, thrombosis<hr/></td>
              <td align="left" valign="bottom">Oral prednisone<hr/></td>
              <td align="left" valign="bottom">Lesions improved in one week<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">59 years/F<hr/></td>
              <td align="left" valign="bottom">Small-vessel vasculitis, thrombosis<hr/></td>
              <td align="left" valign="bottom">Oral prednisone<hr/></td>
              <td align="left" valign="bottom">Lost to follow-up<hr/></td>
            </tr>
            <tr>
              <td rowspan="5" align="left" valign="top">Ullrich K et al.
[<xref ref-type="bibr" rid="B4">4</xref>]<hr/></td>
              <td align="left" valign="bottom">45 years/M<hr/></td>
              <td align="left" valign="bottom">Not reported<hr/></td>
              <td align="left" valign="bottom">Oral prednisone<hr/></td>
              <td align="left" valign="bottom">Initially improved, but symptoms recurred with attempts to taper the steroid dose<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">49 years/F<hr/></td>
              <td align="left" valign="bottom">Thrombosis, perivascular neutrophils, and karyorrhetic debris<hr/></td>
              <td align="left" valign="bottom">Supportive, G-CSF<hr/></td>
              <td align="left" valign="bottom">Resolution of lesions with abstinence from cocaine<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">27 years/F<hr/></td>
              <td align="left" valign="bottom">Lekocytoclastic vasculitis, thrombosis<hr/></td>
              <td align="left" valign="bottom">Oral prednisone<hr/></td>
              <td align="left" valign="bottom">Lesions resolved with abstinence, arthralgia and neutropenia improved rapidly with prednisone<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">29 years/F<hr/></td>
              <td align="left" valign="bottom">Not reported<hr/></td>
              <td align="left" valign="bottom">Supportive care, oral steroids<hr/></td>
              <td align="left" valign="bottom">Lesions resolved with abstinence, septal perforation &amp; arthralia improved with steroids<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">55 years/F<hr/></td>
              <td align="left" valign="bottom">Lekocytoclastic vascultis, thrombosis<hr/></td>
              <td align="left" valign="bottom">Steroids, cyclophosphamide<hr/></td>
              <td align="left" valign="bottom">Rapid resolution of lesions<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Bradford M et al.
[<xref ref-type="bibr" rid="B7">7</xref>]<hr/></td>
              <td align="left" valign="bottom">57 years/F<hr/></td>
              <td align="left" valign="bottom">Intravascular thrombosis, no vasculitis<hr/></td>
              <td align="left" valign="bottom">Filgrastim for neutropenia<hr/></td>
              <td align="left" valign="bottom">Lesions resolved spontaneously, neutropenia improved with filgrastim<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">22 years/F<hr/></td>
              <td align="left" valign="bottom">Leucocytoclastic vasculitis, thrombosis<hr/></td>
              <td align="left" valign="bottom">Steroids<hr/></td>
              <td align="left" valign="bottom">Lesions and neutropenia improved rapidly<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Buchanan JA et al.
[<xref ref-type="bibr" rid="B8">8</xref>]<hr/></td>
              <td align="left" valign="bottom">Not specified/M<hr/></td>
              <td align="left" valign="bottom">Not done<hr/></td>
              <td align="left" valign="bottom">Subcutaneous phentolamine to both ears<hr/></td>
              <td align="left" valign="bottom">No improvement<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Walsh NMG et al.
[<xref ref-type="bibr" rid="B9">9</xref>]<hr/></td>
              <td align="left" valign="bottom">39 years/F<hr/></td>
              <td align="left" valign="bottom">Thrombosis, leucocytoclastic vasculitis<hr/></td>
              <td align="left" valign="bottom">Anticoagulation, skin debridement and grafting<hr/></td>
              <td align="left" valign="bottom">No new lesions with discontinuation of cocaine, skin lesions healed after multiple full thickness skin grafts<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">49 years/F<hr/></td>
              <td align="left" valign="bottom">Thrombosis, no evidence of vasculitis<hr/></td>
              <td align="left" valign="bottom">Supportive care<hr/></td>
              <td align="left" valign="bottom">Lesions improved, recurrences with cocaine use<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Waller JM et al.
[<xref ref-type="bibr" rid="B10">10</xref>]<hr/></td>
              <td align="left" valign="bottom">38 years/F<hr/></td>
              <td align="left" valign="bottom">Leukocytoclastic vasculitis, thrombosis<hr/></td>
              <td align="left" valign="bottom">Supportive care<hr/></td>
              <td align="left" valign="bottom">Lesions improved, recurrences with cocaine use<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">43 years/F<hr/></td>
              <td align="left" valign="bottom">Thrombosis of dermal vessels<hr/></td>
              <td align="left" valign="bottom">Supportive care<hr/></td>
              <td align="left" valign="bottom">Lesions improved, recurrences with cocaine use<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Farhat EK et al.
[<xref ref-type="bibr" rid="B11">11</xref>]<hr/></td>
              <td align="left" valign="bottom">43 years/F<hr/></td>
              <td align="left" valign="bottom">Extensive thrombosis, no vasculitis<hr/></td>
              <td align="left" valign="bottom">Supportive care<hr/></td>
              <td align="left" valign="bottom">Not specified<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">41 years/F<hr/></td>
              <td align="left" valign="bottom">Thrombosis with no vasculitis<hr/></td>
              <td align="left" valign="bottom">Not specified<hr/></td>
              <td align="left" valign="bottom">Not specified<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Click J
[<xref ref-type="bibr" rid="B12">12</xref>]<hr/></td>
              <td align="left" valign="bottom">29 years/F<hr/></td>
              <td align="left" valign="bottom">Subepidermal bullous dermatitis, lymphocytic perivascular infiltrate<hr/></td>
              <td align="left" valign="bottom">Skin grafts<hr/></td>
              <td align="left" valign="bottom">Lesions were healing well after 4 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Geller L et al.
[<xref ref-type="bibr" rid="B13">13</xref>]<hr/></td>
              <td align="left" valign="bottom">50 years/F<hr/></td>
              <td align="left" valign="bottom">Lecocytoclastic vasculitis, thrombosis<hr/></td>
              <td align="left" valign="bottom">Not specified<hr/></td>
              <td align="left" valign="bottom">Not specified<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Han C et al.
[<xref ref-type="bibr" rid="B14">14</xref>]<hr/></td>
              <td align="left" valign="bottom">52 years/F<hr/></td>
              <td align="left" valign="bottom">Thrombotic vasculopathy, no vasculitis<hr/></td>
              <td align="left" valign="bottom">Steroids (iv &amp; oral), dalteparin, warfarin<hr/></td>
              <td align="left" valign="bottom">Lesions and neutropenia improved, had recurrences in with repeat cocaine use, which improved with oral prednisone<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Ching J et al.
[<xref ref-type="bibr" rid="B15">15</xref>]/<break/>Mouzakis J et al.
[<xref ref-type="bibr" rid="B16">16</xref>]<hr/></td>
              <td align="left" valign="bottom">54 years/F<hr/></td>
              <td align="left" valign="bottom">Small vessel thrombosis, perivascular mononuclear infiltrates<hr/></td>
              <td align="left" valign="bottom">IV steroids, left AKA, skin debridement, allografts<hr/></td>
              <td align="left" valign="bottom">Developed extensive skin necrosis requiring debridement and skin grafts<hr/></td>
            </tr>
            <tr>
              <td rowspan="2" align="left" valign="top">Jacob RS et al.
[<xref ref-type="bibr" rid="B17">17</xref>]<hr/></td>
              <td align="left" valign="bottom">41 years/F<hr/></td>
              <td align="left" valign="bottom">Epidermal necrosis, vascular thrombosis, leukocytoclasis<hr/></td>
              <td align="left" valign="bottom">Oral prednisone<hr/></td>
              <td align="left" valign="bottom">Resolution of the majority of the patient&#x2019;s lesions<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">48 years/F<hr/></td>
              <td align="left" valign="bottom">Lymphocytic infiltrate, occlusive vasculopathy, neovascularization<hr/></td>
              <td align="left" valign="bottom">Oral prednisone<hr/></td>
              <td align="left" valign="bottom">Lesions improved<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Lung D et al.
[<xref ref-type="bibr" rid="B18">18</xref>]<hr/></td>
              <td align="left" valign="bottom">44 years/F<hr/></td>
              <td align="left" valign="bottom">Extensive thrombotic vasculopathy<hr/></td>
              <td align="left" valign="bottom">Not specified<hr/></td>
              <td align="left" valign="bottom">Not specified<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Zwang NA et al.
[<xref ref-type="bibr" rid="B19">19</xref>]<hr/></td>
              <td align="left" valign="bottom">52 years/M<hr/></td>
              <td align="left" valign="bottom">Leukocytoclastic vasculitis<hr/></td>
              <td align="left" valign="bottom">Oral prednisone<hr/></td>
              <td align="left" valign="bottom">Lesions healed completely in 3 weeks<hr/></td>
            </tr>
            <tr>
              <td rowspan="4" align="left" valign="top">Chung C et al.
[<xref ref-type="bibr" rid="B20">20</xref>]<hr/></td>
              <td align="left" valign="bottom">46 years/F<hr/></td>
              <td align="left" valign="bottom">Small-vessel vascultits with thrombosis<hr/></td>
              <td align="left" valign="bottom">Steroids<hr/></td>
              <td align="left" valign="bottom">Initial improvement, lost to follow-up<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">46 years/F<hr/></td>
              <td align="left" valign="bottom">Multiple Intravascular thrombi<hr/></td>
              <td align="left" valign="bottom">IV methyl-prednisolone<hr/></td>
              <td align="left" valign="bottom">Gradual improvement initially, lost to follow-up<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">37 years/M<hr/></td>
              <td align="left" valign="bottom">Leucocytoclastic vasculitis<hr/></td>
              <td align="left" valign="bottom">Supportive<hr/></td>
              <td align="left" valign="bottom">Rapid improvement of skin lesions<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">50 years/M<hr/></td>
              <td align="left" valign="bottom">Leucocytoclastic vasculitis, panniculitis<hr/></td>
              <td align="left" valign="bottom">Supportive, antibiotics<hr/></td>
              <td align="left" valign="bottom">Rapid improvement of skin lesions<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">Jenkins J et al.
[<xref ref-type="bibr" rid="B21">21</xref>]<hr/></td>
              <td align="left" valign="bottom">47 years/M<hr/></td>
              <td align="left" valign="bottom">Leucocytoclastic vascultits, occlusive vasculopathy<hr/></td>
              <td align="left" valign="bottom">Oral &amp; topical steroids, aspirin, pentoxifylline<hr/></td>
              <td align="left" valign="bottom">Lesions resolved over 3 months<hr/></td>
            </tr>
            <tr>
              <td align="left" valign="bottom">John S et al.
[<xref ref-type="bibr" rid="B22">22</xref>]<hr/></td>
              <td align="left" valign="bottom">52 years/F<hr/></td>
              <td align="left" valign="bottom">Thrombotic vasculopathy, no vasculitis<hr/></td>
              <td align="left" valign="bottom">Supportive, surgical debridement<hr/></td>
              <td align="left" valign="bottom">Had new lesions with repeat cocaine use and necrotic ulceration of old lesions requiring surgical debridement<hr/></td>
            </tr>
            <tr>
              <td align="left">Arora et al. [current report]</td>
              <td align="left">44 years/F</td>
              <td align="left">Leucocytoclastic vasculitis, thrombosis</td>
              <td align="left">Surgical debridement, pain control, AKA, IV methyl-prednisolone for recurrent lesions</td>
              <td align="left">Recurrent lesions improved significantly with IV methylprednisolone</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <p>Abbreviations: <italic>M</italic>&#x2009;=&#x2009;male, <italic>F</italic>&#x2009;=&#x2009;female, <italic>AKA</italic>&#x2009;=&#x2009;above knee amputation, <italic>IV</italic>&#x2009;=&#x2009;intravenous.</p>
        </table-wrap-foot>
      </table-wrap>
      <p>Levamisole was an FDA-approved drug but was withdrawn for use in humans in the USA in 1999 due to reports of serious adverse effects such as agranulocytosis, thrombocytopenia, arthritis, and LIV
[<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. However, it is still available for animal use in the United States, Canada, and South America
[<xref ref-type="bibr" rid="B26">26</xref>]. In the presence of alternative and more efficacious veterinary antihelminthics, such as ivermectin
[<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>], the reasons for continued availability of levamisole for animal use are poorly understood, especially in light of the emerging data on the potential dangers of its addition to cocaine.</p>
      <p>The practice of adulterating cocaine with levamisole has increased significantly in recent years
[<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Several theories exist to explain the reasons for adulterating cocaine with levamisole. One explanation may be levamisole&#x2019;s ability to potentiate the psychotropic effects of cocaine
[<xref ref-type="bibr" rid="B26">26</xref>]. Stimulant effects of cocaine are mediated by the blockage of presynaptic reuptake pumps for the monoamine neurotransmitters dopamine, norepinephrine, and serotonin in the central and peripheral nervous systems leading to their enhanced activity
[<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>]. Animal data suggest that levamisole may have an inhibitory action on monoamine oxidase and catechol-O-methyltransferase, the enzymes that metabolize catecholamine neurotransmitters
[<xref ref-type="bibr" rid="B26">26</xref>]. Therefore, levamisole may potentially inhibit the degradation of these stimulatory neurotransmitters, prolonging the duration of their action and adding to the reuptake-inhibition effect of cocaine. Clinically, this may result in enhanced psychotropic effects
[<xref ref-type="bibr" rid="B26">26</xref>]. Antihelminthic properties of levamisole are due to its species-specific agonistic action at nicotinic acetylcholine receptors of the muscle cells of nematodes
[<xref ref-type="bibr" rid="B32">32</xref>]. Cocaine may also act on the nicotinic acetylcholine receptors of humans, resulting in increased dopaminergic reuptake inhibition and glutamatergic activity
[<xref ref-type="bibr" rid="B33">33</xref>]. Although unlikely due to species-specific action of levamisole, it is theoretically possible that cocaine and levamisole may have a synergistic action at nicotinic acetylcholine receptors resulting in increased nicotinic and dopaminergic effects
[<xref ref-type="bibr" rid="B26">26</xref>]. Also, studies in horses have suggested that levamisole may get metabolized to aminorex, an amphetamine derivative with stimulant effects similar to cocaine and amphetamine
[<xref ref-type="bibr" rid="B34">34</xref>]. Other possible explanation for using levamisole as a cocaine adulterant may be its use as a &#x201C;marker&#x201D; or &#x201C;signature&#x201D; compound by manufacturers to trace its market distribution
[<xref ref-type="bibr" rid="B26">26</xref>]. Some media reports suggest that levamisole is used as a cutting agent for cocaine because it adds bulk and weight to powdered crack cocaine while retaining the appearance and look of pure cocaine, and it also has the ability to pass cocaine purity tests used by drug dealers. Levamisole-induced cutaneous vasculitis has been reported both with smoked crack cocaine
[<xref ref-type="bibr" rid="B17">17</xref>] and inhaled powdered cocaine
[<xref ref-type="bibr" rid="B21">21</xref>], indicating that both are adulterated with levamisole.</p>
      <p>In addition to levamisole, other commonly used cocaine adulterants include local anesthetics, sugars, stimulants (such as caffeine, ephedrine, phenylpropanolamine, and amphetamines); toxins (such as quinine and strychnine); and inert compounds
[<xref ref-type="bibr" rid="B35">35</xref>]. Among these cocaine adulterants, only stimulants have been associated with vasculitis upon chronic use. Unlike LIV, the vasculitis associated with chronic stimulant use is usually cerebral or systemic in distribution
[<xref ref-type="bibr" rid="B35">35</xref>].</p>
      <p>As LIV is usually associated with the generation of autoantibodies such as p-ANCA, ANA, and lupus anticoagulant, it may be difficult to differentiate it from autoimmune disorders such as Wegener&#x2019;s granulomatosis and other small-vessel vasculitides. The exact pathogenic mechanisms responsible for the formation of these autoantibodies remain elusive. Recent reports have suggested that, due to its ability to act as a hapten, levamisole may cause increased formation of antibodies to various antigens and therefore lead to an immune response involving the opsonization and eventual destruction of the leukocytes
[<xref ref-type="bibr" rid="B33">33</xref>].</p>
      <p>Before the recognition of levamisole as an adulterant in the cocaine supply, cocaine alone was associated with an p-ANCA-positive pseudovasculitis in some previous reports
[<xref ref-type="bibr" rid="B36">36</xref>]. Although clinical presentation and laboratory findings of pseudovasculitis may be similar to true vasculitis, biopsy specimens in pseudovasculitis patients do not reveal the typical histopathologic findings seen in patients with true vasculitis
[<xref ref-type="bibr" rid="B36">36</xref>]. Moreover, there is a possibility that these cocaine-related pseudovasculitis cases were actually caused by unrecognized contamination with levamisole.</p>
      <p>Adulteration of the majority of the cocaine supply entering United States with levamisole is concerning, especially in view of the high frequency of cocaine use in this country. According to the August 2005 National Survey on Drug Use and Health (NSDUH) Report, more than 5.9 million (2.5%) persons aged 12 years or older used cocaine in 2002-2003
[<xref ref-type="bibr" rid="B37">37</xref>].</p>
      <p>Based on published reports, Levamisole-induced cutaneous vasculitis in cocaine users is more commonly seen in women
[<xref ref-type="bibr" rid="B3">3</xref>]. Clinical features commonly include a tender purpuric rash in a retiform/reticular distribution with or without necrosis
[<xref ref-type="bibr" rid="B3">3</xref>]. In addition to leukopenia and neutropenia, laboratory results are usually positive for different types of auto-antibodies such as c-ANCA, p-ANCA, ANA, and lupus anticoagulant
[<xref ref-type="bibr" rid="B3">3</xref>]. Recurrence or exacerbation of skin lesions with cocaine use have been reported in some cases. Skin biopsy shows either a mixed pattern of leukocytoclastic and thrombotic vasculitis or an isolated thrombotic vasculopathy
[<xref ref-type="bibr" rid="B3">3</xref>].</p>
      <p>Cessation of cocaine use and supportive care of LIV-related skin lesions lead to resolution of symptoms in most of the cases. Steroids have been used in a significant number of previously reported cases with a variable response. The recurrent lesions in our patient improved significantly after intravenous methylprednisolone. However, due to the risk of increased susceptibility to superimposed infections, steroid use should be limited to more severe cases that fail to respond to supportive care. Patients should be educated about the possible adverse effects of future cocaine use. Extensive skin involvement and necrosis may need surgical debridement and skin grafting. As happened in our patient, in extreme cases that involve extensive necrosis, amputation may be required to contain necrosis and infection.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>Adulteration of cocaine with levamisole is widely prevalent in United States. Levamisole may cause cutaneous vasculitis and neutropenia in people with cocaine use. History of cocaine use should be explored in patients presenting with a rash and neutropenia, and testing for levamisole exposure should be performed in selected patients. In cases with extensive involvement, this condition may lead to disfigurement by causing necrosis of skin, soft tissue, and cartilage.</p>
      <sec>
        <title>Informed consent</title>
        <p>Written informed consent was obtained from the patient for publication of this case report and all accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p>
      </sec>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>None of the authors has any financial conflicts or competing interests to disclose.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>NA conceived of the case report, performed the literature search, and drafted and revised the manuscript. TJ and RB acquired, analyzed, and interpreted the data. SN revised the manuscript. All authors read and approved the final draft.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Buchanan</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Heard</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Burbach</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Wilson</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Dart</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Prevalence of levamisole in urine toxicology screens positive for cocaine in an inner-city hospital</article-title>
          <source>JAMA</source>
          <year>2011</year>
          <volume>305</volume>
          <issue>16</issue>
          <fpage>1657</fpage>
          <lpage>1658</lpage>
          <pub-id pub-id-type="doi">10.1001/jama.2011.531</pub-id>
          <pub-id pub-id-type="pmid">21521846</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <collab>Centers for Disease Control and Prevention (CDC)</collab>
          <article-title>Agranulocytosis associated with cocaine use&#x2014;four States, March 2008-November 2009</article-title>
          <source>MMWR Morb Mortal Wkly Rep</source>
          <year>2009</year>
          <volume>58</volume>
          <fpage>1381</fpage>
          <lpage>1385</lpage>
          <pub-id pub-id-type="pmid">20019655</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Gross</surname>
            <given-names>RL</given-names>
          </name>
          <name>
            <surname>Brucker</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Bahce-Altuntas</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Abadi</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Lipoff</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Kotlyar</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Barland</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Putterman</surname>
            <given-names>C</given-names>
          </name>
          <article-title>A novel cutaneous vasculitis syndrome induced by levamisole-contaminated cocaine</article-title>
          <source>Clin Rheumatol</source>
          <year>2011</year>
          <volume>30</volume>
          <issue>10</issue>
          <fpage>1385</fpage>
          <lpage>1392</lpage>
          <pub-id pub-id-type="doi">10.1007/s10067-011-1805-3</pub-id>
          <pub-id pub-id-type="pmid">21706168</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ullrich</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Koval</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Koval</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Bapoje</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hirsh</surname>
            <given-names>JM</given-names>
          </name>
          <article-title>Five consecutive cases of a cutaneous vasculopathy in users of levamisole-adulterated cocaine</article-title>
          <source>J Clin Rheumatol</source>
          <year>2011</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>193</fpage>
          <lpage>196</lpage>
          <pub-id pub-id-type="pmid">21617558</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Amery</surname>
            <given-names>WK</given-names>
          </name>
          <name>
            <surname>Bruynseels</surname>
            <given-names>JP</given-names>
          </name>
          <article-title>Levamisole, the story and the lessons</article-title>
          <source>Int J Immunopharmacol</source>
          <year>1992</year>
          <volume>14</volume>
          <issue>3</issue>
          <fpage>481</fpage>
          <lpage>486</lpage>
          <pub-id pub-id-type="doi">10.1016/0192-0561(92)90179-O</pub-id>
          <pub-id pub-id-type="pmid">1618599</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Macfarlane</surname>
            <given-names>DG</given-names>
          </name>
          <name>
            <surname>Bacon</surname>
            <given-names>PA</given-names>
          </name>
          <article-title>Levamisole-induced vasculitis due to circulating immune complexes</article-title>
          <source>Br Med J</source>
          <year>1978</year>
          <volume>1</volume>
          <issue>6110</issue>
          <fpage>407</fpage>
          <lpage>408</lpage>
          <pub-id pub-id-type="doi">10.1136/bmj.1.6110.407</pub-id>
          <pub-id pub-id-type="pmid">146534</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Bradford</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rosenberg</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Moreno</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dumyati</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Bilateral necrosis of earlobes and cheeks: another complication of cocaine contaminated with levamisole</article-title>
          <source>Ann Intern Med</source>
          <year>2010</year>
          <volume>152</volume>
          <issue>11</issue>
          <fpage>758</fpage>
          <lpage>759</lpage>
          <pub-id pub-id-type="pmid">20513844</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Buchanan</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Vogel</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Eberhardt</surname>
            <given-names>AM</given-names>
          </name>
          <article-title>Levamisole-induced occlusive necrotizing vasculitis of the ears after use of cocaine contaminated with levamisole</article-title>
          <source>J Med Toxicol</source>
          <year>2011</year>
          <volume>7</volume>
          <issue>1</issue>
          <fpage>83</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1007/s13181-010-0097-3</pub-id>
          <pub-id pub-id-type="pmid">20549422</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Walsh</surname>
            <given-names>NMG</given-names>
          </name>
          <name>
            <surname>Green</surname>
            <given-names>PJ</given-names>
          </name>
          <name>
            <surname>Burlingame</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Pasternak</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hanly</surname>
            <given-names>JG</given-names>
          </name>
          <article-title>Cocaine-related retiform purpura: evidence to incriminate the adulterant, levamisole</article-title>
          <source>J Cutan Pathol</source>
          <year>2010</year>
          <volume>37</volume>
          <issue>12</issue>
          <fpage>1212</fpage>
          <lpage>1219</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1600-0560.2010.01613.x</pub-id>
          <pub-id pub-id-type="pmid">20738457</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Waller</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Feramisco</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Alberta-Wszolek</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>McCalmont</surname>
            <given-names>TH</given-names>
          </name>
          <name>
            <surname>Fox</surname>
            <given-names>LP</given-names>
          </name>
          <article-title>Cocaine-associated retiform purpura and neutropenia: is levamisole the culprit?</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2010</year>
          <volume>63</volume>
          <issue>3</issue>
          <fpage>530</fpage>
          <lpage>535</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaad.2010.01.055</pub-id>
          <pub-id pub-id-type="pmid">20304523</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Farhat</surname>
            <given-names>EK</given-names>
          </name>
          <name>
            <surname>Moorhead</surname>
            <given-names>TT</given-names>
          </name>
          <name>
            <surname>Chaffing</surname>
            <given-names>ML</given-names>
          </name>
          <name>
            <surname>Douglass</surname>
            <given-names>MC</given-names>
          </name>
          <article-title>Levamisole-induced cutaneous necrosis mimicking coagulopathy</article-title>
          <source>Arch Dermatol</source>
          <year>2010</year>
          <volume>146</volume>
          <issue>11</issue>
          <fpage>1320</fpage>
          <lpage>1321</lpage>
          <pub-id pub-id-type="doi">10.1001/archdermatol.2010.335</pub-id>
          <pub-id pub-id-type="pmid">21079086</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Click</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Levamisole-induced retiform purpura</article-title>
          <source>J Drug Dermatol</source>
          <year>2011</year>
          <volume>10</volume>
          <issue>2</issue>
          <fpage>217</fpage>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Geller</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Whang</surname>
            <given-names>TB</given-names>
          </name>
          <name>
            <surname>Mercer</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Phelps</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Retiform purpura: a new stigmata of illicit drug use?</article-title>
          <source>Dermatol Online J</source>
          <year>2011</year>
          <volume>17</volume>
          <issue>2</issue>
          <fpage>7</fpage>
          <pub-id pub-id-type="pmid">21382290</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Han</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sreenivasan</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Dutz</surname>
            <given-names>JP</given-names>
          </name>
          <article-title>Reversible retiform purpura: a sign of cocaine use</article-title>
          <source>CMAJ</source>
          <year>2011</year>
          <volume>183</volume>
          <issue>9</issue>
          <fpage>597</fpage>
          <lpage>600</lpage>
          <pub-id pub-id-type="doi">10.1503/cmaj.101005</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ching</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>DJ</given-names>
            <suffix>Jr</suffix>
          </name>
          <article-title>Levamisole-induced necrosis of skin, soft tissue, and bone: case report and review of literature</article-title>
          <source>J Burn Care Res</source>
          <year>2012</year>
          <volume>33</volume>
          <issue>1</issue>
          <fpage>1</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1097/BCR.0b013e31823347f6</pub-id>
          <pub-id pub-id-type="pmid">21959208</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mouzakis</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Somboonwit</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Lakshmi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Rumbak</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sinnott</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Cherpelis</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Keshishian</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Levamisole-induced necrosis of the skin and neutropenia following intranasal cocaine use: a newly recognized syndrome</article-title>
          <source>J Drugs Dermatol</source>
          <year>2011</year>
          <volume>10</volume>
          <issue>10</issue>
          <fpage>1204</fpage>
          <lpage>1207</lpage>
          <pub-id pub-id-type="pmid">21968674</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jacob</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Silva</surname>
            <given-names>CY</given-names>
          </name>
          <name>
            <surname>Powers</surname>
            <given-names>JG</given-names>
          </name>
          <name>
            <surname>Schieke</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Mendese</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Burlingame</surname>
            <given-names>RW</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>DD</given-names>
          </name>
          <name>
            <surname>Wolpowitz</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Graber</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Mahalingam</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Levamisole-induced vasculopathy: a report of 2 cases and a novel histopathologic finding</article-title>
          <source>Am J Dermatopathol</source>
          <year>2012</year>
          <volume>34</volume>
          <issue>2</issue>
          <fpage>208</fpage>
          <lpage>213</lpage>
          <pub-id pub-id-type="doi">10.1097/DAD.0b013e31821cc0bf</pub-id>
          <pub-id pub-id-type="pmid">22094232</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lung</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Lynch</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Agrawal</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Armenian</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Banh</surname>
            <given-names>K</given-names>
          </name>
          <article-title>Images in emergency medicine, adult female with rash on lower extremities. vasculopathic purpura and neutropenia caused by levamisole-contaminated cocaine</article-title>
          <source>Ann Emerg Med</source>
          <year>2011</year>
          <volume>57</volume>
          <issue>3</issue>
          <fpage>307</fpage>
          <lpage>311</lpage>
          <pub-id pub-id-type="doi">10.1016/j.annemergmed.2010.05.009</pub-id>
          <pub-id pub-id-type="pmid">21353913</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Zwang</surname>
            <given-names>NA</given-names>
          </name>
          <name>
            <surname>Van Wagner</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Rose</surname>
            <given-names>S</given-names>
          </name>
          <article-title>A case of levamisole-induced systemic vasculitis and cocaine-induced midline destructive lesion: a case report</article-title>
          <source>J Clin Rheumatol</source>
          <year>2011</year>
          <volume>17</volume>
          <issue>4</issue>
          <fpage>197</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">21617545</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chung</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Tumeh</surname>
            <given-names>PC</given-names>
          </name>
          <name>
            <surname>Birnbaum</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>BH</given-names>
          </name>
          <name>
            <surname>Sharp</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>McCoy</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Mercurio</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Craft</surname>
            <given-names>N</given-names>
          </name>
          <article-title>Characteristic purpura of the ears, vasculitis, and neutropenia&#x2013;a potential public health epidemic associated with levamisole-adulterated cocaine</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2011</year>
          <volume>65</volume>
          <issue>4</issue>
          <fpage>722</fpage>
          <lpage>725</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jaad.2010.08.024</pub-id>
          <pub-id pub-id-type="pmid">21658797</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B21">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Jenkins</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Babu</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hsu-Hung</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Robinson-Bostom</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Kroumpouzos</surname>
            <given-names>G</given-names>
          </name>
          <article-title>ANCA-positive necrotizing vasculitis and thrombotic vasculopathy induced by levamisole-adulterated cocaine: a distinctive clinicopathologic presentation</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2011</year>
          <volume>65</volume>
          <issue>1</issue>
          <fpage>14</fpage>
          <lpage>16</lpage>
        </mixed-citation>
      </ref>
      <ref id="B22">
        <mixed-citation publication-type="journal">
          <name>
            <surname>John</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Manda</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hamrock</surname>
            <given-names>D</given-names>
          </name>
          <article-title>Cocaine-induced thrombotic vasculopathy</article-title>
          <source>Am J Med Sci</source>
          <year>2011</year>
          <volume>342</volume>
          <issue>6</issue>
          <fpage>524</fpage>
          <lpage>526</lpage>
          <pub-id pub-id-type="doi">10.1097/MAJ.0b013e31822979f1</pub-id>
          <pub-id pub-id-type="pmid">21817879</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B23">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Parkinson</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Cano</surname>
            <given-names>PO</given-names>
          </name>
          <name>
            <surname>Jerry</surname>
            <given-names>LM</given-names>
          </name>
          <name>
            <surname>Capek</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Shibata</surname>
            <given-names>HR</given-names>
          </name>
          <name>
            <surname>Mansell</surname>
            <given-names>PW</given-names>
          </name>
          <name>
            <surname>Lewis</surname>
            <given-names>MG</given-names>
          </name>
          <name>
            <surname>Marquis</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Complications of cancer immunotherapy with levamisole</article-title>
          <source>Lancet</source>
          <year>1977</year>
          <volume>1</volume>
          <issue>8022</issue>
          <fpage>1129</fpage>
          <lpage>1132</lpage>
          <pub-id pub-id-type="pmid">68226</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B24">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Segal</surname>
            <given-names>AW</given-names>
          </name>
          <name>
            <surname>Pugh</surname>
            <given-names>SF</given-names>
          </name>
          <name>
            <surname>Levi</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Loewi</surname>
            <given-names>G</given-names>
          </name>
          <article-title>Levamisole-induced arthritis in Crohn&#x2019;s disease</article-title>
          <source>Br Med J</source>
          <year>1977</year>
          <volume>2</volume>
          <issue>6086</issue>
          <fpage>555</fpage>
          <pub-id pub-id-type="pmid">890414</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B25">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Laux-End</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Inabenit</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gerber</surname>
            <given-names>HA</given-names>
          </name>
          <name>
            <surname>Bianchetti</surname>
            <given-names>MG</given-names>
          </name>
          <article-title>Vasculitis associated with levamisole and circulating autoantibodies</article-title>
          <source>Arch Dis Child</source>
          <year>1996</year>
          <volume>75</volume>
          <issue>4</issue>
          <fpage>355</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="pmid">8984931</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B26">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Chang</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Osterloh</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Levamisole: a dangerous new adulterant</article-title>
          <source>Clin Pharmacol Ther</source>
          <year>2010</year>
          <volume>88</volume>
          <issue>3</issue>
          <fpage>408</fpage>
          <lpage>411</lpage>
          <pub-id pub-id-type="doi">10.1038/clpt.2010.156</pub-id>
          <pub-id pub-id-type="pmid">20668440</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B27">
        <mixed-citation publication-type="journal">
          <name>
            <surname>McKellar</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Marriner</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Bogan</surname>
            <given-names>J</given-names>
          </name>
          <article-title>Comparison of ivermectin, oxfendazole and levamisole for use as anthelmintics during the periparturient period in sheep</article-title>
          <source>Vet Rec</source>
          <year>1988</year>
          <volume>122</volume>
          <issue>23</issue>
          <fpage>558</fpage>
          <lpage>560</lpage>
          <pub-id pub-id-type="doi">10.1136/vr.122.23.558</pub-id>
          <pub-id pub-id-type="pmid">3413926</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B28">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Hembry</surname>
            <given-names>FG</given-names>
          </name>
          <name>
            <surname>Miller</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Sims</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Rodriguez</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Stagg</surname>
            <given-names>LC</given-names>
          </name>
          <article-title>Efficacy of repeated doses of levamisole, morantel, fenbendazole, and ivermectin against gastrointestinal nematodes in ewes</article-title>
          <source>Am J Vet Res</source>
          <year>1986</year>
          <volume>47</volume>
          <issue>8</issue>
          <fpage>1677</fpage>
          <lpage>1679</lpage>
          <pub-id pub-id-type="pmid">3755877</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B29">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Casale</surname>
            <given-names>JF</given-names>
          </name>
          <name>
            <surname>Corbeil</surname>
            <given-names>EM</given-names>
          </name>
          <name>
            <surname>Hays</surname>
            <given-names>PA</given-names>
          </name>
          <article-title>Identification of levamisole impurities found in illicit cocaine exhibits</article-title>
          <source>Microgram J</source>
          <year>2008</year>
          <volume>6</volume>
          <issue>3,4</issue>
          <fpage>82</fpage>
          <lpage>89</lpage>
        </mixed-citation>
      </ref>
      <ref id="B30">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Rothman</surname>
            <given-names>RB</given-names>
          </name>
          <name>
            <surname>Baumann</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Dersch</surname>
            <given-names>CM</given-names>
          </name>
          <name>
            <surname>Romero</surname>
            <given-names>DV</given-names>
          </name>
          <name>
            <surname>Rice</surname>
            <given-names>KC</given-names>
          </name>
          <name>
            <surname>Carroll</surname>
            <given-names>FI</given-names>
          </name>
          <name>
            <surname>Partilla</surname>
            <given-names>JS</given-names>
          </name>
          <article-title>Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin</article-title>
          <source>Synapse</source>
          <year>2001</year>
          <volume>39</volume>
          <issue>1</issue>
          <fpage>32</fpage>
          <lpage>41</lpage>
          <pub-id pub-id-type="doi">10.1002/1098-2396(20010101)39:1&lt;32::AID-SYN5&gt;3.0.CO;2-3</pub-id>
          <pub-id pub-id-type="pmid">11071707</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B31">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Howell</surname>
            <given-names>LL</given-names>
          </name>
          <name>
            <surname>Kimmel</surname>
            <given-names>HL</given-names>
          </name>
          <article-title>Monoamine transporters and psychostimulant addiction</article-title>
          <source>Biochem Pharmacol</source>
          <year>2008</year>
          <volume>75</volume>
          <issue>1</issue>
          <fpage>196</fpage>
          <lpage>217</lpage>
          <pub-id pub-id-type="doi">10.1016/j.bcp.2007.08.003</pub-id>
          <pub-id pub-id-type="pmid">17825265</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B32">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Martin</surname>
            <given-names>RJ</given-names>
          </name>
          <article-title>Modes of action of anthelmintic drugs</article-title>
          <source>Vet J</source>
          <year>1997</year>
          <volume>154</volume>
          <issue>1</issue>
          <fpage>11</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1016/S1090-0233(05)80005-X</pub-id>
          <pub-id pub-id-type="pmid">9265850</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B33">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Raymon</surname>
            <given-names>LP</given-names>
          </name>
          <name>
            <surname>Isenschmid</surname>
            <given-names>DS</given-names>
          </name>
          <article-title>Letter to the editor: the possible role of levamisole in illicit cocaine preparations</article-title>
          <source>J Anal Toxicol</source>
          <year>2009</year>
          <volume>33</volume>
          <issue>9</issue>
          <fpage>620</fpage>
          <lpage>622</lpage>
          <pub-id pub-id-type="pmid">20040138</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B34">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Ho</surname>
            <given-names>EN</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>DK</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>GN</given-names>
          </name>
          <name>
            <surname>Wan</surname>
            <given-names>TS</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>AS</given-names>
          </name>
          <name>
            <surname>Wong</surname>
            <given-names>CH</given-names>
          </name>
          <name>
            <surname>Soma</surname>
            <given-names>LR</given-names>
          </name>
          <name>
            <surname>Rudy</surname>
            <given-names>JA</given-names>
          </name>
          <name>
            <surname>Uboh</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sams</surname>
            <given-names>R</given-names>
          </name>
          <article-title>Aminorex and rexamino as metabolites of levamisole in the horse</article-title>
          <source>Anal Chim Acta</source>
          <year>2009</year>
          <volume>638</volume>
          <issue>1</issue>
          <fpage>58</fpage>
          <lpage>68</lpage>
          <pub-id pub-id-type="doi">10.1016/j.aca.2009.02.033</pub-id>
          <pub-id pub-id-type="pmid">19298880</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B35">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shannon</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Clinical toxicity of cocaine adulterants</article-title>
          <source>Ann Emerg Med</source>
          <year>1988</year>
          <volume>17</volume>
          <issue>11</issue>
          <fpage>1243</fpage>
          <lpage>1247</lpage>
          <pub-id pub-id-type="doi">10.1016/S0196-0644(88)80078-7</pub-id>
          <pub-id pub-id-type="pmid">2903705</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B36">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Friedman</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Wolfsthal</surname>
            <given-names>SD</given-names>
          </name>
          <article-title>Cocaine-induced pseudovasculitis</article-title>
          <source>Mayo Clin Proc</source>
          <year>2005</year>
          <volume>80</volume>
          <issue>5</issue>
          <fpage>671</fpage>
          <lpage>673</lpage>
          <pub-id pub-id-type="doi">10.4065/80.5.671</pub-id>
          <pub-id pub-id-type="pmid">15887436</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B37">
        <mixed-citation publication-type="other">
          <collab>Office of Applied Studies (OAS), Substance Abuse and Mental Health Services Administration (SAMHSA)</collab>
          <source>The 2005 National Survey on Drug Use and Health Report</source>
          <comment>
            <ext-link ext-link-type="uri" xlink:href="http://www.oas.samhsa.gov/2k5/cocaine/cocaine.pdf">http://www.oas.samhsa.gov/2k5/cocaine/cocaine.pdf</ext-link>
          </comment>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
